Nabriva Therapeutics plc [NASDAQ: NBRV] plunged by $0.0 during the normal trading session on Wednesday and reaching a high of $1.40 during the day while it closed the day at $1.39. The company report on June 3, 2021 that Nabriva Announces Changes to its Board of Directors.
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that Dr. Mark Corrigan and Lisa Dalton have joined the Company’s Board of Directors. In addition, after many years of service Dr. George Talbot has notified the company of his decision not to stand for re-election to the Board of Directors. Dr. Talbot is expected to continue his service on the Board of Directors until the conclusion of his term at the 2021 Annual General Meeting of Shareholders.
Dan Burgess, Chairman of the Nabriva Board of Directors commented, “We are excited to welcome Mark back to the Nabriva Board and are absolutely delighted to welcome Lisa to the Nabriva Board. Mark’s extensive experience in the industry from both a scientific and executive level brings a wealth of experience and knowledge to the Board. Likewise, the addition of Lisa’s extensive experience in human resources and executive management will be an invaluable asset to the organization. Mr. Burgess added, “On behalf of the entire Board, I would also like to thank Dr. Talbot for his efforts, input and many contributions to Nabriva over the past 12 years.”.
Nabriva Therapeutics plc stock has also loss -6.08% of its value over the past 7 days. However, NBRV stock has declined by -28.35% in the 3 months of the year. Over the past six months meanwhile, it has lost -67.45% and lost -42.56% year-on date.
The market cap for NBRV stock reached $49.96 million, with 26.41 million shares outstanding and 24.78 million shares in the current float. Compared to the average trading volume of 4.27M shares, NBRV reached a trading volume of 3164267 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Nabriva Therapeutics plc [NBRV]:
Wedbush have made an estimate for Nabriva Therapeutics plc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on March 19, 2020. The new note on the price target was released on May 02, 2019, representing the official price target for Nabriva Therapeutics plc stock. Previously, the target price had yet another drop from $9 to $7, while H.C. Wainwright kept a Buy rating on NBRV stock.
The Average True Range (ATR) for Nabriva Therapeutics plc is set at 0.13, with the Price to Sales ratio for NBRV stock in the period of the last 12 months amounting to 7.35. The Price to Book ratio for the last quarter was 0.67, with the Price to Cash per share for the same quarter was set at 1.52.
NBRV stock trade performance evaluation
Nabriva Therapeutics plc [NBRV] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.08. With this latest performance, NBRV shares dropped by -19.65% in over the last four-week period, additionally sinking by -67.45% over the last 6 months – not to mention a drop of -81.55% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NBRV stock in for the last two-week period is set at 39.28, with the RSI for the last a single of trading hit 36.67, and the three-weeks RSI is set at 40.09 for Nabriva Therapeutics plc [NBRV]. The present Moving Average for the last 50 days of trading for this stock 1.5626, while it was recorded at 1.4140 for the last single week of trading, and 3.4140 for the last 200 days.
Nabriva Therapeutics plc [NBRV]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Nabriva Therapeutics plc [NBRV] shares currently have an operating margin of -1315.42 and a Gross Margin at +68.45. Nabriva Therapeutics plc’s Net Margin is presently recorded at -1382.22.
Return on Total Capital for NBRV is now -113.39, given the latest momentum, and Return on Invested Capital for the company is -121.27. Return on Equity for this stock declined to -186.76, with Return on Assets sitting at -91.10. When it comes to the capital structure of this company, Nabriva Therapeutics plc [NBRV] has a Total Debt to Total Equity ratio set at 23.32. Additionally, NBRV Total Debt to Total Capital is recorded at 18.91, with Total Debt to Total Assets ending up at 13.22. Long-Term Debt to Equity for the company is recorded at 17.16, with the Long-Term Debt to Total Capital now at 13.92.
Reflecting on the efficiency of the workforce at the company, Nabriva Therapeutics plc [NBRV] managed to generate an average of -$965,056 per employee. Receivables Turnover for the company is 1.51 with a Total Asset Turnover recorded at a value of 0.07.Nabriva Therapeutics plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.80 and a Current Ratio set at 4.30.
Earnings per share (EPS) analysis for Nabriva Therapeutics plc [NBRV] stock
With the latest financial reports released by the company, Nabriva Therapeutics plc posted -1.4/share EPS, while the average EPS was predicted by analysts to be reported at -1.6/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 12.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NBRV.
Nabriva Therapeutics plc [NBRV]: Insider Ownership positions
There are presently around $4 million, or 11.90% of NBRV stock, in the hands of institutional investors. The top three institutional holders of NBRV stocks are: FMR LLC with ownership of 1,343,459, which is approximately -6.003% of the company’s market cap and around 1.80% of the total institutional ownership; FRAZIER MANAGEMENT LLC, holding 425,650 shares of the stock with an approximate value of $0.59 million in NBRV stocks shares; and AISLING CAPITAL MANAGEMENT LP, currently with $0.27 million in NBRV stock with ownership of nearly New of the company’s market capitalization.
Positions in Nabriva Therapeutics plc stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 14 institutional holders increased their position in Nabriva Therapeutics plc [NASDAQ:NBRV] by around 734,077 shares. Additionally, 14 investors decreased positions by around 1,017,376 shares, while 9 investors held positions by with 1,309,604 shares. The mentioned changes placed institutional holdings at 3,061,057 shares, according to the latest SEC report filing. NBRV stock had 8 new institutional investments in for a total of 497,225 shares, while 6 institutional investors sold positions of 203,274 shares during the same period.